PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis

25 August 2023 (12:15 - 13:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Ali Khan

Brown University, Providence (United States of America)

7 More presentations in this session

Presentation thumbnail

Severe hypertriglyceridemia and its correlation with clinical atherosclerosis and pancreatitis investigated in beta-quantification

Associate Professor Y. Winhofer (Vienna, AT)

Abstract Slides Video

Presentation thumbnail

Comparison of estimated LDL cholesterol equations with direct measurement

Mr G. Velisaris (Athens, GR)

Abstract Slides Video

Presentation thumbnail

The Cycle study: a prospective study on cholesterol levels during the menstrual cycle

Miss J. Mulder (Rotterdam, NL)

Abstract Slides Video

Presentation thumbnail

Low-density lipoprotein cholesterol reduction and short-term incidence of ASCVD in the population-based cohort study LATINO

Professor C. Gavina (Porto, PT)

Abstract Slides Video

Presentation thumbnail

Association of statin use and outcomes in elderly with multiple risk factors: insight from the CORE registry Thailand.

Doctor P. Chichareon (Hat Yai, TH)

Abstract Slides Video

Access the full session

Session thumbnail

Risk factors and prevention: lipids (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 12:15 CET

You may be interested in

Congress Presentation

PCSK9 inhibition: new insights

Congress Presentation

Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Congress Presentation

Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources